Skip to main content

Colleague Stories: Tim Dack

Careers , Nottingham

Colleague Stories: Tim Dack

Tim Dack discusses his career at Quotient Sciences

It is great to be part of such an inspiring organization. Working in a fulfilling, positive environment makes me look forward to coming in to work each day. 

-Tim Dack

Tim Dack, Purchasing Operations Manager, talks about his experience working in the Procurement department at Quotient Sciences Nottingham, UK facility.

What does a Purchasing Operations Manager do at Quotient Sciences?

As part of my role, I oversee the department responsible for Purchase Order Processing (POP), ensuring that Purchase Orders are fulfilled and expedited to the respective site, to meet the operational demands of the business. Some other aspects of my role involve managing relationships with suppliers, working closely with finance, quality and other functions to onboard new suppliers to the business, and training staff on the ordering process.

What does a typical day look like for a role in the Purchasing function?

A typical day in Purchasing involves assessing approved requisitions, prioritizing, and converting them to orders to be placed with suppliers, ensuring we effectively communicate all relevant correspondence with stakeholders across the business. We also monitor and respond to all incoming requests, both from colleagues and suppliers. Each day is different, though, and there are always different requests that can come our way.

How has your career progressed since joining the company?

When I first joined Quotient Sciences over a decade ago, I had been in transition in my career and wasn’t sure what my next steps were at the time. I took a role as a contract, Stores Assistant position and a month later, I was offered the opportunity to convert to a full-time position in that role. I took it and did my best to provide the best service I could in that role. Over the years, I was fortunate to have had training and development, which led to a steady progression of added responsibilities in the Purchasing department, leading up to the management role which I now have.  

What experience did you have before you worked at Quotient Sciences?

I had existing skills around systems and customer service before joining the company, but no applicable knowledge of stores, warehousing or other principles of procurement. Everything I have learned has been during my time here, and my prior experience in a customer service role helped with engagement with departments around the site.

What learning or qualifications have you gained while working here?

I’ve gained a lot of skills organically during my time here. Among them have been how to be a more effective communicator, how to manage my time better, and how to use systems like Excel in a more advanced way. I’ve also been privileged to attend courses that have given me more insight into Procurement, including courses from The Chartered Institute of Procurement & Supply (CIPS), which is a globally-recognized professional organization related to the procurement and supply profession.

What do you enjoy most about your role, and what do you find most challenging?

I enjoy the variety of challenges that the pharmaceutical industry presents. Collaboration is integral to a successful Procurement department and there is a huge sense of achievement when we are involved in delivery of successful projects that positively impact the business. The value we drive isn’t all about cost savings but about assessing and optimizing relationships with suppliers and the programs or services that we have with them, to ensure we’re getting the most out of what we put in.

Reacting to unpredictable situations is one of the more challenging aspects of the role. For example, sourcing business critical PPE in the height of the pandemic was one I’ll remember likely for my whole career. I learned a lot about vendor management as we were going through that, to say the very least! I’m a believer that, whether personally or professionally, each challenge we face, overcome and learn from leaves us better prepared for the future.

What’s the team like?

I work with a fantastic team of 11 colleagues who have a wealth of knowledge and experience. We’re all like-minded individuals with shared values and approaches to the day-to-day responsibilities and tasks. Aside from working well together in the office, we also go for team meals and nights out as often as we can.

What advice would you give to someone applying for a role in your team?

If you’re keen to learn, we’re geared up to guide you as far as you want to go. We encourage growth and want to offer the opportunity to excel.

What do you like most about working at Quotient Sciences?

It is great to be part of such an inspiring organization. Working in a fulfilling, positive environment makes me look forward to coming in to work each day. 

Colleague Stories: Kate Foster

Careers , Nottingham

Colleague Stories: Kate Foster

Kate Foster discusses her career at Quotient Sciences

Kate Foster discusses her career at Quotient Sciences, and her experiences working at our Nottingham, UK facility.

"Quotient Sciences provides an exciting, fast paced environment to work in. The company understands individual needs and allows flexibility and is good at adapting in an ever-changing world."

-Kate Foster

What does a Clinical Performance & Compliance Manager do at Quotient Sciences?

In my role, I have responsibility for scheduling, training, compliance, and continuous improvement in our clinic. One of my goals is to ensure everyone is set up to deliver our studies confidently and in compliance with good clinical practices (GCP) and Quotient Sciences’ clinical protocols and standard operating procedures (SOPs).

I have direct line management of our scheduling manager as well as our training and compliance team to ensure we are getting the best out of our team, to meet the needs of the business and our people. I also directly manage a team of Clinical Data Coordinators with oversight of data collection and transcription into client databases and study set up.

I have a passion for continuous improvement and seek opportunities that allow us to work smarter, not harder, in the clinic. In my role, I am always looking at where we can apply principles of Lean Six Sigma to make improvements in how we deliver projects, whether that is to reduce waste and variation in our processes, increase the quality of our programs, or to improve colleague or volunteer wellbeing and engagement.

Describe a typical day in the clinic.

No two days are the same in our clinic!

On a typical day, there is a buzz of activity starting at 7am when the early shift starts and prepares our volunteers for dosing or study procedures. Some days, we take blood samples and perform safety procedures, such as ECGs and vital signs, regularly throughout the day. Other times, volunteers will just have one set of procedures in the morning.

Once the peak of activities are completed in the morning, our team are busy looking after volunteers, setting up and preparing the clinic for the next day, taking time for training, attending study meetings, or catching up on other day-to-day tasks.

In my role, a typical day for me includes work on various improvement projects or plans for what’s coming up in the weeks and months ahead, and meetings with my immediate and wider team to provide support and advice.

How has your career progressed since joining us?

I’ve held various roles since joining Quotient Sciences initially in 2012 as a Clinical Scientist. I worked closely with volunteers on our wards and was trained up to perform procedures such as taking blood samples, ECGs, vitals, and dosing volunteers. I later took a keen interest in getting involved in preparing study documentation and progressed to my next role as a Clinical Deputy. In this role, I supported the Clinical Lead with oversight of studies, preparing documents, attending study meetings, and delivering study training to the wider team.

To expand my knowledge even more, I took a role within the Project Management team as a Clinical Project Coordinator in 2015. It was interesting to get involved in projects from start up to completion and archiving, but I really did miss working with the volunteers. I returned to the clinic in 2016 as a Clinical Lead, where I managed a team of technicians and nurses responsible for delivering studies.

I built a wealth of experience in delivering all types of studies and was later promoted to a Senior Clinical Lead with oversight of a larger team. I was also a key leader in driving more general clinic improvement projects, which led me to pursue a role focused on continuous improvement as an Operational Excellence and Performance Specialist. My main focus became driving improvement projects within the clinic, and that has led me to my current role.

What experience did you have before you worked at Quotient Sciences, and what learning or qualification have you gained in your time with the company so far?

Over the years and within the different roles that I’ve held at Quotient Sciences, I have learned so much about clinical trials and the pharmaceutical industry. I pursued a Bachelor of Science degree in Psychology and following graduation, I started in my first role at Quotient Sciences in 2012 as a Clinical Scientist. For this role, a science degree was desirable but not mandatory.

I have completed training in Good Clinical Practice (GCP) protocols. GCP is critical for how trials are designed and conducted, and there are regulatory standards that must be upheld and involving areas such as documentation for the clinical protocol, record keeping, and training. I am also certified in providing Immediate Life Support (ILS). Most recently, in relation to my interests in continuous improvement, I have gained a Green Belt in Lean Six Sigma.

At Nottingham, we also have implemented a Mental Health First Aider program, which is an internal program for colleagues. I have also completed training to be part of this program so I can aid colleagues who may need support.

What do you enjoy most about your role? And what is most challenging?

I love working in an exciting, fast paced environment. No two studies are the same and it is great to be such an integral part of the molecule journey. That said, sometimes, there’s just not enough hours in the day to achieve all that I want to achieve! But it’s great to keep busy and stay motivated, just need to be good at prioritizing!

What’s the team like?

We have a great team here who always rally to help each other and achieve great things! Our clinical team is a large team, and many of our team members work shifts so it is often challenging to get everyone together. The wider team, although we don’t often cross paths, when we do, everyone is always really friendly and approachable, and people will often go out of their way to make time for you even when they have a busy schedule.

What advice would you give to someone applying for a role in your team?

Work hard, stay focused, ask lots of questions and push yourself outside your comfort zone. Take every opportunity you get to learn new skills, listen to experts in other areas and observe what people do in other departments to gain a full understanding of the business.

What do you like most about working at Quotient Sciences?

It is a great company to work for, they understand individual needs and allow flexibility and the company is good at adapting in an ever-changing world.

Tufts CSDD Demonstrates Multi-Million Dollar Benefits of Translational Pharmaceutics®

Articles & Publications , Translational Pharmaceutics®

Tufts CSDD Demonstrates Multi-Million Dollar Benefits of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

The Tufts CSDD study assessed development cycle times and their financial benefits by using data compiled on completed Translational Pharmaceutics projects to benchmark against industry drug development durations. On average, Translational Pharmaceutics was shown to accelerate development by more than 12 months, with each month of development time saved resulting in a $9.5 million reduction in R&D costs per approved new drug. Further gains are achieved from products reaching the market sooner, translating into total financial benefits to drug sponsors of more than $200 million per approved new drug.

Translational Pharmaceutics is a platform that integrates formulation development and real-time adaptive manufacturing and clinical research to accelerate drug development. It has been used widely by pharmaceutical and biotech companies to advance molecules from first-in-human to proof-of-concept and accelerate the development and optimization of clinical formulations.

“Our own studies have demonstrated significant benefits, and we are pleased that Tufts CSDD has accurately quantified the time and cost benefits of our unique Translational Pharmaceutics approach to drug development,” said Mark Egerton, Ph.D., Quotient CEO. “Quotient Sciences has worked hard over the past decade to develop this innovative platform to help our customers lower costs, accelerate development, and improve R&D productivity.”

"Despite long-standing efforts by the pharma industry to operate more efficiently, traditional drug development paradigms and outsourcing models still present a number of challenges for today’s drug developers," said Joseph A. DiMasi, Ph.D., director of economic analysis at Tufts CSDD and principal investigator for the study. "The outcomes from this research indicate that Translational Pharmaceutics can create substantial time savings and financial benefits to pharma and biotech companies."

Peter Scholes, Ph.D., Quotient CSO, said, “Translational Pharmaceutics accelerates the development timeline by integrating drug product manufacturing into the clinical research program. Emerging clinical data are then used in real time to inform the optimization of a clinical formulation and maximize the potential for the drug to achieve its desired therapeutic effect.”

Read the full PDF version here

Quotient Sciences Expands UK Formulation and Analytical Capabilities

News & Announcements

Quotient Sciences Expands UK Formulation and Analytical Capabilities

Drug Development & Manufacturing Partners - Quotient Sciences
NOTTINGHAM, UK; August 24,2022 – Quotient Sciences, a drug development and manufacturing accelerator, has completed a £1.5 million expansion of its early development and manufacturing facility in Reading, UK.

The investment has doubled formulation development and analytical capabilities at the site, increased office space, and created 40 new technical and scientific jobs including formulators and analytical chemists.

“Our investment in Reading is in response to strong market demand, direct feedback from our customer base, and to maximize utilization of our UK-based operational footprint,,” said Mark Egerton, CEO of Quotient Sciences.

“As well as increased formulation development and analytical capabilities, the expansion increases our capacity to support  programs as they progress through development phases, providing our customers with further improved services.”

Quotient Sciences employs more than 1,300 talented individuals across six operating sites in the UK and US. The 48,000 sq ft Reading facility currently employs 75 people across a range of scientific disciplines.

Egerton added: “We are committed to a growth strategy that supports our customers on both sides of the Atlantic, with stand-alone development and manufacturing services, or fully integrated Translational Pharmaceutics® programs that deliver substantial time and cost benefits.

“We will continue to liaise with existing and potential customers to ensure we are meeting their current and future needs and expect to announce further expansions of both UK and US operations in the near future.”

Acquired in 2017, Quotient Sciences tripled the manufacturing footprint of the Reading facility in 2018, increasing the total number of manufacturing suites to 13. The site focuses on small-molecule drug products from the pre-clinical stage through to Phase I-III clinical trials, with significant expertise in poorly soluble compounds and a broad range of technologies including spray drying, hot-melt extrusion, lipidic systems, and particle size reduction methodologies.

View the press release here

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR

News & Announcements

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR

Ensysce Biosciences and Quotient Sciences logos

Partnership further expedites Ensysce’s development pipeline

NOTTINGHAM, UK; August 31, 2022 – Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient Sciences, a drug development and manufacturing accelerator, today announced a partnership to support the development and clinical testing of PF614-MPAR.

PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.

Quotient Sciences is currently using its integrated Translational Pharmaceutics® platform to identify a PF614-MPAR formulation that allows conversion into oxycodone within the prescribed dose range but reduces conversion to oxycodone at higher than prescribed dose levels in an overdose scenario.

The formulation will be an optimized composition that balances dose and release rate, with the candidate formulations being tested in the clinic having been selected from emerging clinical data in order to achieve the desired exposure profile, allowing formulation optimization in humans rather than preclinical species. 

Mark Egerton, PhD, CEO of Quotient Sciences, said: "We are pleased to be partnering with Ensysce to accelerate the development of their PF614-MPAR program. Quotient Sciences’ ability to integrate formulation and clinical services under a single organization will expedite Ensysce’s development timeline and provide patients who are suffering with a safer option for pain relief faster.”

Lynn Kirkpatrick, PhD, CEO of Ensysce Biosciences, commented: “Opioids have been a longstanding and important type of treatment for moderate to severe pain, but they are prone to abuse and overdose. This widespread problem for patients and society results in significant costs to the healthcare system, which we are trying to address with our two proprietary technology platforms.”

“The PF614-MPAR program is designed to fill a great unmet need for effective pain medications that reduce the risk of abuse and specifically prescription drug overdose. This partnership serves as validation of our mission and ultimately our platforms. We continue to make strong progress towards our clinical development of PF614 and are excited to partner with Quotient Sciences to develop PF614-MPAR, as we believe we will be bringing to market important therapeutic options for those in severe pain.”

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.

About Ensysce Biosciences

Ensysce Biosciences San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Ensysce Biosciences Company Contact
Lynn Kirkpatrick, PhD
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact
MZ Group North America
Shannon Devine
(203) 741-8811
[email protected]

SOURCE: Ensysce Biosciences Inc.

Click here to access the official release

HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

News & Announcements , Customer Milestone , Synthesis-to-Clinic® , ADME

HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

Quotient Sciences

Integrated Quotient Sciences Synthesis-to-Clinic® Program Will Support HTD1801’s Clinical Development and Regulatory Submission Package

ROCKVILLE, USA; SHENZHEN, CHINA; and NOTTINGHAM, UK: December 15, 2022 – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.

The agreement will see Quotient Sciences perform a 14C human absorption, distribution, metabolism, and excretion (ADME) study for HighTide’s lead drug candidate, HTD1801, to generate data to support HTD1801’s clinical development.    

HTD1801 is a first-in-class new molecular entity. HighTide’s continued clinical progress with HTD1801 includes an ongoing Phase 2 study for the treatment of type 2 diabetes (T2DM), the initiation of a global Phase 2b study for the treatment of nonalcoholic steatohepatitis (NASH), and the successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for primary sclerosing cholangitis (PSC).      

The U.S. FDA has granted HTD1801 Fast Track designation in both NASH and PSC.

Quotient Sciences will be providing a fully integrated Synthesis-to-Clinic® program, from radiosynthesis of the 14C-labeled drug substance to the design and conduct of the human ADME study and delivery of the final clinical study report. The company is currently commencing radiochemistry activities and finalizing the clinical study design.

Mark Egerton, PhD, CEO of Quotient Sciences, said: “We are excited to share our expertise in 14C-enabled drug development with HighTide to support their HTD1801 program, which has the potential to help many patients suffering from T2DM, NASH, and PSC worldwide. Our unique Synthesis-to-Clinic offering streamlines the entire human ADME process by integrating radiolabeled formulation development, real-time drug product manufacturing, and clinical testing in a single program of work led by a single project manager, reducing timelines and getting new medicines to patients faster.”

Liping Liu, PhD, Founder and CEO of HighTide, added: “We are very pleased to enter this collaboration with Quotient Sciences. Both parties have extensive expertise and experience in their respective fields. The study will help us better understand the ADME properties of HTD1801 to continue to advance our global clinical development programs. We expect the alliance to greatly facilitate our clinical progress by completing the ADME program in a more streamlined, time- and cost-effective manner.”


About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

About HighTide Therapeutics
HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of innovative multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program.

HighTide Therapeutics Company Contact
Jeffrey Dao
[email protected]
+1-650-580-3872

Subscribe to